GleamWall
中文EN

APVO Aptevo Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1671584 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY4.0%
TTM EPS YoY100.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-239.1%
ROA-125.9%
ROIC (approx.)-1,145.2%
Asset turnover—

Leverage & solvency

Liabilities / assets71.1%
Debt / equity0.00x
Current ratio1.50x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$14.54M$14.38M
SG&A expense$11.77M$10.22M
Operating income-$26.31M-$24.60M
Pretax income-$25.97M-$24.13M
Income tax$0—
Net income-$25.97M-$24.13M
EBITDA-$26.07M-$24.25M
EPS (basic)-87.27-31,460.23
EPS (diluted)-87.27-31,460.23
Weighted avg. shares (diluted)315,535767
Balance sheet
Cash & equivalents$21.62M$8.71M
Current assets$23.08M$10.66M
PP&E, net$303,000$543,000
Total assets$27.19M$15.59M
Current liabilities$6.05M$6.21M
Total liabilities$9.81M$10.84M
Shareholders' equity$17.38M$4.75M
Shares outstanding997,8304,051
Cash flow statement
Operating cash flow-$25.59M-$23.79M
Investing cash flow$0$0
Financing cash flow$38.50M$15.60M
Depreciation & amortization$240,000$352,000
Stock-based compensation$96,000$1.07M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.